JP6382191B2 - Ｃａｒの抗腫瘍活性のための毒性管理 - Google Patents

Ｃａｒの抗腫瘍活性のための毒性管理 Download PDF

Info

Publication number
JP6382191B2
JP6382191B2 JP2015521838A JP2015521838A JP6382191B2 JP 6382191 B2 JP6382191 B2 JP 6382191B2 JP 2015521838 A JP2015521838 A JP 2015521838A JP 2015521838 A JP2015521838 A JP 2015521838A JP 6382191 B2 JP6382191 B2 JP 6382191B2
Authority
JP
Japan
Prior art keywords
cells
cytokine
patient
cell
car
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015521838A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015522081A (ja
Inventor
カール エイチ． ジューン
カール エイチ． ジューン
ブルース エル． リバイン
ブルース エル． リバイン
マイケル ディー． カロス
マイケル ディー． カロス
ステファン グラップ
ステファン グラップ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Hospital of Philadelphia CHOP
Original Assignee
Childrens Hospital of Philadelphia CHOP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49916566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6382191(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Childrens Hospital of Philadelphia CHOP filed Critical Childrens Hospital of Philadelphia CHOP
Publication of JP2015522081A publication Critical patent/JP2015522081A/ja
Application granted granted Critical
Publication of JP6382191B2 publication Critical patent/JP6382191B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Endocrinology (AREA)
JP2015521838A 2012-07-13 2013-07-12 Ｃａｒの抗腫瘍活性のための毒性管理 Active JP6382191B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261671482P 2012-07-13 2012-07-13
US61/671,482 2012-07-13
US201361782982P 2013-03-14 2013-03-14
US61/782,982 2013-03-14
PCT/US2013/050267 WO2014011984A1 (en) 2012-07-13 2013-07-12 Toxicity management for anti-tumor activity of cars

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018085102A Division JP6563554B2 (ja) 2012-07-13 2018-04-26 Ｃａｒの抗腫瘍活性のための毒性管理

Publications (2)

Publication Number Publication Date
JP2015522081A JP2015522081A (ja) 2015-08-03
JP6382191B2 true JP6382191B2 (ja) 2018-08-29

Family

ID=49916566

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2015521838A Active JP6382191B2 (ja) 2012-07-13 2013-07-12 Ｃａｒの抗腫瘍活性のための毒性管理
JP2018085102A Active JP6563554B2 (ja) 2012-07-13 2018-04-26 Ｃａｒの抗腫瘍活性のための毒性管理
JP2018150287A Withdrawn JP2019006782A (ja) 2012-07-13 2018-08-09 Ｃａｒの抗腫瘍活性のための毒性管理
JP2019136179A Active JP7034125B2 (ja) 2012-07-13 2019-07-24 Ｃａｒの抗腫瘍活性のための毒性管理
JP2022030740A Active JP7682820B2 (ja) 2012-07-13 2022-03-01 Ｃａｒの抗腫瘍活性のための毒性管理
JP2024194132A Pending JP2025013518A (ja) 2012-07-13 2024-11-06 Ｃａｒの抗腫瘍活性のための毒性管理

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2018085102A Active JP6563554B2 (ja) 2012-07-13 2018-04-26 Ｃａｒの抗腫瘍活性のための毒性管理
JP2018150287A Withdrawn JP2019006782A (ja) 2012-07-13 2018-08-09 Ｃａｒの抗腫瘍活性のための毒性管理
JP2019136179A Active JP7034125B2 (ja) 2012-07-13 2019-07-24 Ｃａｒの抗腫瘍活性のための毒性管理
JP2022030740A Active JP7682820B2 (ja) 2012-07-13 2022-03-01 Ｃａｒの抗腫瘍活性のための毒性管理
JP2024194132A Pending JP2025013518A (ja) 2012-07-13 2024-11-06 Ｃａｒの抗腫瘍活性のための毒性管理

Country Status (21)

Country Link
US (4) US20150202286A1 (enExample)
EP (5) EP3721901A1 (enExample)
JP (6) JP6382191B2 (enExample)
KR (1) KR102204029B1 (enExample)
CN (4) CN108379586A (enExample)
AU (2) AU2013289967B2 (enExample)
BR (1) BR112015000660A8 (enExample)
CA (1) CA2878928C (enExample)
DK (4) DK4461308T3 (enExample)
EA (1) EA201590210A1 (enExample)
ES (4) ES2941370T3 (enExample)
FI (2) FI4019041T3 (enExample)
HR (2) HRP20250822T1 (enExample)
HU (4) HUE072215T2 (enExample)
IN (1) IN2014DN11155A (enExample)
LT (4) LT3338794T (enExample)
MX (2) MX2015000438A (enExample)
PL (3) PL4461308T3 (enExample)
PT (4) PT4019041T (enExample)
SI (2) SI4019041T1 (enExample)
WO (1) WO2014011984A1 (enExample)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20250822T1 (hr) 2012-07-13 2025-09-26 The Trustees Of The University Of Pennsylvania UPRAVLJANJE TOKSIČNOŠĆU ZA PROTUTUMORSKO DJELOVANJE CAR-a
EP3653212B1 (en) 2012-12-20 2023-04-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
ES2814962T3 (es) 2013-02-20 2021-03-29 Novartis Ag Fijación eficaz como objetivo de la leucemia humana primaria utilizando células T modificadas con receptor de antígeno quimérico anti-CD123
PL2958943T3 (pl) 2013-02-20 2020-04-30 The Trustees Of The University Of Pennsylvania Leczenie nowotworu złośliwego za pomocą humanizowanego chimerycznego receptora antygenowego anty-egfrviii
ES3058841T3 (en) 2013-03-15 2026-03-13 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
CA2931684C (en) 2013-12-19 2024-02-20 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
EP4420663A3 (en) 2013-12-20 2024-10-30 Novartis AG Regulatable chimeric antigen receptor
EP4303229A3 (en) 2014-01-21 2024-04-17 Novartis AG Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
SI3888674T1 (sl) * 2014-04-07 2024-08-30 Novartis Ag Zdravljenje raka z uporabo antigenskega himernega receptorja proti-CD19
CA2946511C (en) 2014-04-21 2023-08-22 The Childen's Hospital Of Philadelphia Compositions and methods for treating cytokine-related disorders
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
US10174095B2 (en) 2014-07-21 2019-01-08 Novartis Ag Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
JP6736540B2 (ja) 2014-07-21 2020-08-05 ノバルティス アーゲー Ｃｌｌ−１キメラ抗原受容体を使用した癌の処置
SG10201913765YA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
RU2020117196A (ru) 2014-08-19 2020-10-15 Новартис Аг Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей
JP6839074B2 (ja) 2014-09-17 2021-03-03 ノバルティス アーゲー 養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
CA2963935A1 (en) * 2014-10-08 2016-04-14 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
IL253149B2 (en) 2014-12-29 2023-11-01 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2016115482A1 (en) 2015-01-16 2016-07-21 Novartis Pharma Ag Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
CN113713091A (zh) * 2015-02-06 2021-11-30 新加坡国立大学 工程免疫细胞及其用途和生产方法
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11512289B2 (en) * 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
IL303972A (en) 2015-04-08 2023-08-01 Novartis Ag CD20 treatments, CD22 treatments and combined treatments with CD19 chimeric antigen receptor expressing cell
WO2016168595A1 (en) 2015-04-17 2016-10-20 Barrett David Maxwell Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EP4140492A1 (en) 2015-04-21 2023-03-01 Enlivex Therapeutics Rdo Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
AU2016297014B2 (en) 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
US11747346B2 (en) 2015-09-03 2023-09-05 Novartis Ag Biomarkers predictive of cytokine release syndrome
HUE066644T2 (hu) 2015-09-15 2024-08-28 Acerta Pharma Bv CD19-inhibitor és BTK-inhibitor terápiás kombinációi
CN116121281B (zh) 2015-11-27 2026-01-02 卡瑟里克斯私人有限公司 经遗传修饰的细胞及其用途
IL259576B (en) 2015-12-04 2022-09-01 Novartis Ag grna molecule containing tracr and crrna, pharmaceutical composition containing it and method for preparing cells for immunotherapy
EP3384294B1 (en) * 2015-12-04 2021-10-13 Juno Therapeutics, Inc. Methods and compositions related to toxicity associated with cell therapy
US11413340B2 (en) 2015-12-22 2022-08-16 Novartis Ag Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
JP6853514B2 (ja) * 2015-12-27 2021-03-31 国立大学法人東海国立大学機構 炎症性サイトカインの産生が抑制されるキメラ抗原受容体遺伝子改変リンパ球
JP6884155B2 (ja) * 2016-02-18 2021-06-09 エンリヴェックス セラピューティクス リミテッド 癌治療のための併用免疫療法及びサイトカイン制御療法
WO2018009923A1 (en) * 2016-07-08 2018-01-11 F1 Oncology, Inc. Methods and compositions for transducing lymphocytes and regulating the activity thereof
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
MA44486A (fr) * 2016-03-22 2019-01-30 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Procédés d'intervention précoce pour prévenir ou atténuer la toxicité
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
ES2937699T3 (es) 2016-04-22 2023-03-30 Crage Medical Co Ltd Composiciones y métodos de inmunoterapia celular
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
KR20240036704A (ko) * 2016-06-06 2024-03-20 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 치료법을 이용한 b 세포 악성종양의 치료 방법
US20190336504A1 (en) 2016-07-15 2019-11-07 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
CN110267677A (zh) * 2016-08-01 2019-09-20 诺华股份有限公司 使用与原m2巨噬细胞分子抑制剂组合的嵌合抗原受体治疗癌症
MY200337A (en) 2016-10-07 2023-12-20 Novartis Ag Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain
CN106636090B (zh) * 2016-10-11 2019-08-09 上海优卡迪生物医药科技有限公司 人源白细胞介素6的siRNA、重组表达CAR-T载体及其构建方法和应用
JP7227131B2 (ja) * 2016-12-03 2023-02-21 ジュノー セラピューティクス インコーポレイテッド Ｃａｒ－ｔ細胞の投薬を決定するための方法
EP3548046A2 (en) 2016-12-03 2019-10-09 Juno Therapeutics, Inc. Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
CN108148863B (zh) * 2016-12-05 2019-12-17 上海优卡迪生物医药科技有限公司 一种封闭il6r的用于缓解crs的car-t转基因载体及其构建方法和应用
CN108250301A (zh) * 2016-12-29 2018-07-06 天津天锐生物科技有限公司 一种多靶点嵌合抗原受体
EP3574005B1 (en) 2017-01-26 2021-12-15 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
ES2988795T3 (es) 2017-02-27 2024-11-21 Juno Therapeutics Inc Composiciones, artículos de fabricación y métodos relacionados con la dosificación en terapia celular
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
CA3054621A1 (en) 2017-03-22 2018-09-27 Novartis Ag Compositions and methods for immunooncology
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
WO2018204413A1 (en) * 2017-05-01 2018-11-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Targeted cytokine blockades for car-t therapy
KR20200054160A (ko) 2017-06-02 2020-05-19 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법
CA3064893A1 (en) * 2017-06-08 2018-12-13 Enlivex Therapeutics Ltd. Therapeutic apoptotic cells for cancer therapy
US11648269B2 (en) 2017-08-10 2023-05-16 National University Of Singapore T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof
JP7320498B2 (ja) * 2017-10-02 2023-08-03 ヒューマニジェン，インコーポレイテッド Ｇｍ－ｃｓｆアンタゴニストを使用した免疫療法関連毒性の治療方法
WO2020055932A2 (en) * 2018-09-10 2020-03-19 Humanigen, Inc. Methods of treating immunotherapy-related toxicity using a gm-csf antagonist
WO2019079564A1 (en) * 2017-10-18 2019-04-25 Kite Pharma, Inc. METHODS OF DELIVERY OF CHIMERIC ANTIGEN RECEPTOR IMMUNOTHERAPY
US11999802B2 (en) 2017-10-18 2024-06-04 Novartis Ag Compositions and methods for selective protein degradation
WO2019089855A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
CN112218651A (zh) 2018-01-08 2021-01-12 诺华公司 用于与嵌合抗原受体疗法组合的免疫增强rna
AU2019209428B2 (en) * 2018-01-22 2025-06-26 Endocyte, Inc. Methods of use for CAR T cells
CA3090089A1 (en) 2018-02-06 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
CN108300807A (zh) * 2018-02-07 2018-07-20 安徽古生物科技有限公司 针对第四代嵌合抗原受体car载体pcr鉴定的方法
TW202000229A (zh) 2018-02-23 2020-01-01 美商安德賽特公司 Car t細胞療法之順序方法
US20210046159A1 (en) * 2018-03-09 2021-02-18 Ospedale San Raffaele S.R.L. Il-1 antagonist and toxicity induced by cell therapy
EP3765154A4 (en) * 2018-03-14 2021-11-24 Celledit LLC MODIFICATION OF IMMUNE CELLS TO REDUCE TOXICITY AND USES THEREOF IN ADOPTIVE CELL THERAPY
JP2021518160A (ja) 2018-03-15 2021-08-02 ケーエスキュー セラピューティクス， インコーポレイテッド 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
SG11202010996QA (en) 2018-05-23 2020-12-30 Nat Univ Singapore Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
US20200054675A1 (en) 2018-06-01 2020-02-20 Washington University Suppression of cytokine release syndrome in chimeric antigen receptor cell therapy
MX2020013017A (es) * 2018-06-01 2021-03-02 Mayo Found Medical Education & Res Materiales y metodos para tratar cancer.
JP7438988B2 (ja) 2018-06-13 2024-02-27 ノバルティス アーゲー Ｂｃｍａキメラ抗原受容体及びその使用
CN108949759B (zh) * 2018-07-23 2021-06-01 合肥一兮生物科技有限公司 敲减人IL-15的siRNA、CD19 CAR表达载体、CAR-T细胞及构建方法和应用
JP2021532116A (ja) 2018-07-23 2021-11-25 マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. 同種異系の細胞療法における抗−ｃｄ５抗体薬物コンジュゲート（ａｄｃ）の使用
BR112021002487A2 (pt) * 2018-08-10 2021-07-27 Eutilex Co., Ltd. receptor de antígeno quimérico que se liga a hla-dr e célula car-t
US12240915B2 (en) 2018-08-30 2025-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
CA3116412A1 (en) * 2018-10-31 2020-05-07 Humanigen, Inc. Materials and methods for treating cancer
SG11202105084VA (en) * 2018-11-16 2021-06-29 Juno Therapeutics Inc Methods of dosing engineered t cells for the treatment of b cell malignancies
US10918667B2 (en) 2018-11-20 2021-02-16 Innovative Cellular Therapeutics CO., LTD. Modified cell expressing therapeutic agent and uses thereof
CN120005921A (zh) 2018-12-12 2025-05-16 凯德药业股份有限公司 嵌合抗原和t细胞受体及使用的方法
JP2022524178A (ja) * 2019-01-07 2022-04-28 セルリス パルティシパソエス リミターダ タンデム受容体ｃａｒにおける二重特異性と腫瘍マイクロ環境を変調する方法
CN112430579A (zh) * 2019-08-26 2021-03-02 深圳宾德生物技术有限公司 靶向Her2并干扰IL-6表达的嵌合抗原受体T细胞及其制备方法和应用
CN114761037A (zh) 2019-11-26 2022-07-15 诺华股份有限公司 结合bcma和cd19的嵌合抗原受体及其用途
IL292924A (en) 2019-11-26 2022-07-01 Novartis Ag Chimeric antigen receptors cd19 and cd22 and their uses
EP4100428A4 (en) 2020-02-04 2024-03-06 Seattle Children's Hospital (DBA Seattle Children's Research Institute) CHIMERIC ANTI-DINITROPHENOL ANTIGEN RECEPTORS
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
US20220169694A1 (en) * 2020-02-20 2022-06-02 Kite Pharma, Inc. Chimeric antigen receptor t cell therapy
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
EP3988116A1 (en) * 2020-10-23 2022-04-27 Consejo Superior De Investigaciones Científicas (CSIC) Methods and compositions for the treatment of hematologic malignancies
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
TW202237827A (zh) 2020-12-03 2022-10-01 美商世紀治療股份有限公司 經基因工程改造之細胞及其用途
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
CN116635064A (zh) 2020-12-18 2023-08-22 世纪治疗股份有限公司 具有适应性受体特异性的嵌合抗原受体系统
SI4284512T1 (sl) 2021-01-28 2025-06-30 Regeneron Pharmaceuticals, Inc. Sestavki in postopki za zdravljenje sindroma sproščanja citokinov
CA3172530A1 (en) 2021-02-25 2022-09-01 Spencer PARK Ror1 targeting chimeric antigen receptor
WO2023004055A1 (en) * 2021-07-21 2023-01-26 The Cleveland Clinic Foundation Metabolic and inflammatory markers for car-t cell therapy
WO2023076096A1 (en) * 2021-10-27 2023-05-04 Rush University Medical Center Methods of treating the effects of cytokine storms
WO2023159001A1 (en) * 2022-02-15 2023-08-24 Kite Pharma, Inc. Predicting adverse events from immunotherapy
JP2025535448A (ja) * 2022-10-20 2025-10-24 マイクロ クリスパー プライベート リミテッド 免疫療法におけるサイトカイン放出症候群の軽減

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ATE195022T1 (de) 1987-04-27 2000-08-15 Unilever Nv Spezifische bindungstestverfahren
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US6267722B1 (en) 1998-02-03 2001-07-31 Adeza Biomedical Corporation Point of care diagnostic systems
US6656745B1 (en) 2000-06-02 2003-12-02 Francis X. Cole Devices and methods for a multi-level, semi-quantitative immunodiffusion assay
AU2008207646A1 (en) * 2001-10-04 2008-09-25 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
EP1670787B1 (en) * 2003-09-11 2012-05-30 iTherX Pharma, Inc. Cytokine inhibitors
EP1664796B1 (en) * 2003-09-15 2010-12-15 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate ankylosing spondylitis
US7189522B2 (en) 2005-03-11 2007-03-13 Chembio Diagnostic Systems, Inc. Dual path immunoassay device
KR101741731B1 (ko) 2007-05-21 2017-05-30 앨더바이오 홀딩스 엘엘씨 Ｉｌ-６에 대한 항체 및 이의 용도
WO2008157282A1 (en) * 2007-06-18 2008-12-24 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
US9452227B2 (en) * 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
CN102292106B (zh) 2008-11-25 2016-02-03 奥尔德生物制药公司 Il-6抗体及其用途
WO2010075249A2 (en) * 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
CN102740888B (zh) 2009-11-24 2016-10-12 奥尔德生物制药公司 Il-6抗体及其用途
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
EA026436B9 (ru) 2012-07-04 2017-07-31 Ин Энд Тек С.Р.Л. Шарнирная петля для вращательного движения двери, в частности армированной двери
HRP20250822T1 (hr) 2012-07-13 2025-09-26 The Trustees Of The University Of Pennsylvania UPRAVLJANJE TOKSIČNOŠĆU ZA PROTUTUMORSKO DJELOVANJE CAR-a

Also Published As

Publication number Publication date
EP4019041B1 (en) 2022-12-28
EP4461308A3 (en) 2024-12-11
EP4461308A2 (en) 2024-11-13
EP2872171A4 (en) 2016-02-10
CN111467494B (zh) 2023-05-02
MX2015000438A (es) 2016-04-25
JP2019182874A (ja) 2019-10-24
HRP20230297T1 (hr) 2023-05-12
ES3032321T3 (en) 2025-07-17
CN111467494A (zh) 2020-07-31
BR112015000660A8 (pt) 2019-07-16
JP2018150320A (ja) 2018-09-27
FI4019041T3 (fi) 2023-04-03
LT4461308T (lt) 2025-06-10
HK1253365A1 (en) 2019-06-14
PT3338794T (pt) 2020-04-24
DK4461308T3 (da) 2025-06-23
WO2014011984A1 (en) 2014-01-16
PT2872171T (pt) 2021-03-31
DK3338794T3 (da) 2020-05-04
JP2025013518A (ja) 2025-01-24
SI4461308T1 (sl) 2025-09-30
EP4019041A1 (en) 2022-06-29
CA2878928A1 (en) 2014-01-16
BR112015000660A2 (pt) 2014-01-16
ES2778701T3 (es) 2020-08-11
IN2014DN11155A (enExample) 2015-10-02
HUE053556T2 (hu) 2021-07-28
EA201590210A1 (ru) 2015-08-31
KR20150042784A (ko) 2015-04-21
US20230013642A1 (en) 2023-01-19
CN108379586A (zh) 2018-08-10
EP4461308B1 (en) 2025-04-16
ES2859522T3 (es) 2021-10-04
AU2018203924A1 (en) 2018-06-21
MX2019014761A (es) 2020-02-12
PT4461308T (pt) 2025-07-11
AU2018203924B2 (en) 2020-04-16
LT2872171T (lt) 2021-04-26
EP2872171A1 (en) 2015-05-20
FI4461308T3 (fi) 2025-07-09
PL4461308T3 (pl) 2025-08-11
PT4019041T (pt) 2023-03-29
AU2013289967B2 (en) 2018-03-29
EP2872171B1 (en) 2021-01-06
CA2878928C (en) 2023-03-14
US11273219B2 (en) 2022-03-15
PL2872171T3 (pl) 2021-07-12
CN104427997B (zh) 2020-12-11
AU2013289967A1 (en) 2015-01-22
US20180256712A1 (en) 2018-09-13
ES2941370T3 (es) 2023-05-22
CN104427997A (zh) 2015-03-18
SI4019041T1 (sl) 2023-04-28
LT4019041T (lt) 2023-04-11
EP3338794A1 (en) 2018-06-27
DK2872171T3 (da) 2021-03-08
JP2019006782A (ja) 2019-01-17
HUE072215T2 (hu) 2025-10-28
JP6563554B2 (ja) 2019-08-21
JP7034125B2 (ja) 2022-03-11
KR102204029B1 (ko) 2021-01-19
HRP20250822T1 (hr) 2025-09-26
CN111481667A (zh) 2020-08-04
JP2022066304A (ja) 2022-04-28
PL4019041T3 (pl) 2023-05-08
US20180243411A1 (en) 2018-08-30
JP7682820B2 (ja) 2025-05-26
HUE061555T2 (hu) 2023-07-28
LT3338794T (lt) 2020-05-25
US20150202286A1 (en) 2015-07-23
JP2015522081A (ja) 2015-08-03
US10603378B2 (en) 2020-03-31
EP3721901A1 (en) 2020-10-14
EP3338794B1 (en) 2020-02-26
DK4019041T3 (da) 2023-04-03
HUE048947T2 (hu) 2020-09-28

Similar Documents

Publication Publication Date Title
JP7682820B2 (ja) Ｃａｒの抗腫瘍活性のための毒性管理
US11944647B2 (en) Articles of manufacture and methods for treatment using adoptive cell therapy
HK40069741A (en) Toxicity management for anti-tumor activity of cars
HK40116181B (en) Toxicity management for anti-tumor activity of cars
HK40116181A (en) Toxicity management for anti-tumor activity of cars
HK40039113A (en) Toxicity management for anti-tumor activity of cars
HK40069741B (en) Toxicity management for anti-tumor activity of cars
HK1253365B (en) Toxicity management for anti-tumor activity of cars
EA041322B1 (ru) Контроль над токсичностью в случае противоопухолевой активности химерных антигенных рецепторов (car)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150416

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150331

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170403

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170825

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180611

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180618

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180705

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180801

R150 Certificate of patent or registration of utility model

Ref document number: 6382191

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250